Genetic studies of drug response and side effects in the STAR*D study, part 2

Journal of Clinical Psychiatry

Volumn 70, Issue 9, 2009, Pages 1323-1325

  Garriock, Holly A ^a   Hamilton, Steven P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESCITALOPRAM; FK 506 BINDING PROTEIN; GLUCOCORTICOID RECEPTOR; IONOTROPIC RECEPTOR; NIMODIPINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNK2; SEROTONIN TRANSPORTER; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; VERAPAMIL; VESICULAR MONOAMINE TRANSPORTER 2; ANTIDEPRESSANT AGENT; SLC6A4 PROTEIN, HUMAN;

ARTICLE; COGNITIVE THERAPY; DEPRESSION; DIARRHEA; DNA SEQUENCE; DRUG RESPONSE; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; LIBIDO; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL IDEATION; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; MAJOR DEPRESSION; PHARMACOGENETICS; PSYCHOLOGICAL ASPECT; PSYCHOSEXUAL DISORDER; RANDOMIZED CONTROLLED TRIAL; STATISTICS; SUICIDE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SUICIDE; TREATMENT OUTCOME;

EID: 70350463843     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09ac05522     Document Type: Article

References (25)

1. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804-814. PubMed doi:10.1086/503820
2. Peters EJ, Slager SL, Jenkins GD, et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics. 2009;19(1):1-10. PubMed doi:10.1097/FPC.0b013e3283163ecd
3. Uher R, Huezo-Diaz P, Perroud N, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009;9(4):225-233. PubMed doi:10.1038/tpj.2009.12
4. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164(8):1181-1188. PubMed doi:10.1176/appi.ajp.2007.06111790 (Pubitemid 47292406)
5. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort. Biol Psychiatry. 2008;63(12):1103-1110. PubMed doi:10.1016/j.biopsych.2007.10.026
6. Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12):1319-1325. PubMed doi:10.1038/ng1479 (Pubitemid 39577942)
7. Perlis RH, Moorjani P, Fagerness J, et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR*D study. Neuropsychopharmacology. 2008;33(12):2810-2819. PubMed doi:10.1038/npp.2008.6
8. Heurteaux C, Lucas G, Guy N, et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci. 2006;9(9):1134-1141. PubMed doi:10.1038/nn1749 (Pubitemid 44306306)
9. Teranishi KS, Slager SL, Garriock H, et al. Variants in PDE11A and PDE1A are not associated with citalopram response. (letter) Mol Psychiatry. 2007;12(12):1061-1063. PubMed doi:10.1038/sj.mp.4002074
10. Cabanero M, Laje G, Dtera-Wadleigh S, et al. Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample. Pharmacogenet Genomics. 2009;19(3):235-238. PubMed doi:10.1097/FPC.0b013e328320a3e2
11. Wong ML, Whelan F, Deloukas P, et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci U S A. 2006;103(41):15124-15129. PubMed doi:10.1073/pnas.0602795103 (Pubitemid 44583175)
12. Crowley JJ, Lipsky RH, Lucki I, et al. Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome. Psychiatr Genet. 2008;18(5):248-251. PubMed doi:10.1097/YPG.0b013e3283052ff7
13. Domschke K, Lawford B, Laje G, et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol. 2009;23:1-9. doi:10.1017/S1461145709000030
14. Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One. 2008;3(4):e1872. PubMed doi:10.1371/journal.pone.0001872
15. Wisniewski SR, Rush AJ, Balasubramani GK, et al. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12(2):71-79. PubMed doi:10.1097/00131746-200603000-00002
16. Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007;64(7):783-792. PubMed doi:10.1001/archpsyc.64.7.783 (Pubitemid 47026374)
17. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007;164(10):1530-1538. PubMed doi:10.1176/appi.ajp.2007.06122018 (Pubitemid 350069732)
18. Perlis RH, Purcell S, Fagerness J, et al. Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol Psychiatry. 2007;62(5):536-540. PubMed doi:10.1016/j.biopsych.2006.10.034 (Pubitemid 47284030)
19. Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007;64(6):689-697. PubMed doi:10.1001/archpsyc.64.6.689 (Pubitemid 46878669)
20. Ferreira MAR, O'Donovan MC, Meng YA, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008;40(9):1056-1058. PubMed doi:10.1038/ng.209
21. Casamassima F, Huang J, Fava M, et al. Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. (published online ahead of print April 22, 2009) Am J Med Genet B Neuropsychiatr Genet. 2009. PubMed doi:10.1002/ajmg.b.30962
22. Perlis RH, Laje G, Smoller JW, et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology. 2009;34(7):1819-1828. PubMed doi:10.1038/npp.2009.4
23. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486. PubMed doi:10.1038/428486a
24. Kraft JB, Peters EJ, Slager SL, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry. 2007;61(6):734-742. PubMed doi:10.1016/j.biopsych.2006. 07.017
25. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? a STAR*D report. Am J Psychiatry. 2009;166(5):599-607. PubMed doi:10.1176/appi.ajp.2008.08071027